-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bimekizumab is a monoclonal IgG1 antibody that can selectively inhibit interleukin-17A and interleukin-17F
.
Compared with secukinumab in patients with moderate to severe plaque psoriasis, the efficacy and safety of bimekizumab have not been extensively studied
In this phase 3b trial, we randomly assigned patients with moderate to severe plaque psoriasis at a ratio of 1:1 to inject bimekizumab subcutaneously at a dose of 320 mg every 4 weeks or secukinumab at a dose of 300 mg per week Until the 4th week, every 4 weeks thereafter, until the 48th week
.
At week 16, patients who received bimekizumab were re-randomized at a ratio of 1:2 and received maintenance doses every 4 weeks or every 8 weeks until week 48
As a result, a total of 1005 patients were screened and 743 patients were selected; 373 patients received bimekizumab and 370 received secukinumab
.
At week 16, there were 230 patients (61.
In summary, the results of the study show that in patients with moderate to severe psoriasis, the skin clearance rate after 16 and 48 weeks of treatment with bimekizumab is higher than that of secukinumab treatment, but it is consistent with oral candidiasis (mainly recorded by the researchers).
(Mild or moderate) related
.
Longer and larger trials are needed to determine the comparative effectiveness and risk of interleukin-17 inhibitors on psoriasis
Original source:
Kristian Reich, et al.
Leave a message here
